Results of gen-therapeutic drug «Neovasculgen» in patients with chronic lower limb ischemia: 1 year of observation
Автор: Deev R.V., Kalinin R.E., Chervyakov Y.V., Gryaznov S.G., Mzhavanadze N.D., Kiselev S.L., Isaev A.A., Schwalb P.G., Staroverov I.N., Nersessian E.G.
Журнал: Вестник Национального медико-хирургического центра им. Н.И. Пирогова @vestnik-pirogov-center
Рубрика: Оригинальные статьи
Статья в выпуске: 4 т.6, 2011 года.
Бесплатный доступ
The results of the delayed clinical surveillance inoperable patients with chronic lower limb ischemia (IIa-III degree A.V. Pokrovsky-Fontaine), included in a phase 1-2a clinical trials of the drug on the basis of plasmid gene vascular endothelial growth factor, conducted 1 year after receiving the drug. The study evaluated the clinical and instrumental data, which included the length of treadmill test, ankle-brachial index (ABI), TcO 2, linear velocity of blood flow. It is shown that obtained immediately after treatment, the therapeutic effect is not only stable, but during the year registered an increase. ABI score testified to the hemodynamic success of therapy.
Atherosclerosis, chronic ischemia of lower extremities, vascular endothelial growth factor, neovaskulgen
Короткий адрес: https://sciup.org/140188001
IDR: 140188001
